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Abstract 
The incidence of esophageal adenocarcinoma (EAC) has increased rapidly during the past four 
decades in many Western populations, including North America and Europe. The established 
etiological factors for EAC include gastro-esophageal reflux and obesity, Helicobacter pylori 
infection, tobacco smoking, and consumption of fruit and vegetables. There is a marked male 
predominance of EAC with a male-to-female ratio in incidence of up to 9-to-1. This review 
evaluates the available literature on the reasons for the male predominance, particularly an update 
on epidemiologic evidence from human studies during the past decade. The striking sex 
difference does not seem to be explained by established risk factors, given that the prevalence of 
the etiological factors and the strengths of associations between these factors and EAC risk are 
similar between the sexes. Sex hormonal factors may play a role in the development of EAC; 
estrogenic exposures may prevent such development, while androgens might increase the risk of 
EAC. However, continuing research efforts are still in need to fully understand the reasons for the 
male predominance of EAC. 
Key words: Esophageal adenocarcinoma; male predominance; sex difference; estrogen; sex 
hormones; epidemiology.  
  
The past four decades have witnessed a rapid increase in the incidence of esophageal 
adenocarcinoma (EAC) in the Western societies. EAC is presently the predominant histologic 
type of esophageal malignancy in several North American and European countries.
1, 2
 Among 
52,000 new cases of EAC (41,000 in men and 11,000 in women) worldwide in 2012, 12,000 
(22.8%) occurred in Europe and 11,100 (21.2%) in North America.
3
 The increasing prevalence of 
the main risk factors, gastro-esophageal reflux and obesity, as well as the decreasing prevalence 
of Helicobacter pylori (H. pylori) infection may have contributed to the unprecedented rise in 
EAC incidence.
1, 4
 It is estimated that the incidence of EAC will continue to rise over the coming 
decades.
5
 
EAC is characterized by a marked and enigmatic male predominance with a male-to-
female ratio in incidence of up to 9-to-1.
1, 3, 6, 7
 Such a striking sex difference may be explained 
by both extrinsic and intrinsic exposures which are differentially distributed between the sexes or 
more harmful in men than in women. In this review, we have evaluated the available literature on 
this issue, particularly focusing on the epidemiologic evidence from human studies from the past 
decade.  
 
Search methods 
A systematic search of the literature related to the sex difference of EAC was undertaken, 
starting with a PubMed search. The time period was from an unbounded start date to 30 June 
2015, and only publications in English were reviewed. The full electronic search is listed in the 
supplementary material. Briefly, both key words for the diseases (esophageal cancer or Barrett’s 
esophagus), the topic (sex difference), and the exposures (sex hormonal and reproductive factors) 
were used to identify relevant publications. Epidemiological studies included in this review met 
the following criteria: (1) case-control or cohort studies published as original articles; (2) the 
studied outcome being esophageal cancer/Barrett’s esophagus incidence rather than mortality; (3) 
the association between hypothesized risk factors and the risk of esophageal cancer or Barrett’s 
esophagus being examined. In case of multiple reports on the same population, only the most 
recent or informative ones were included. We further reviewed the reference lists of relevant 
narrative reviews, systematic reviews and meta-analyses, and papers of interest to identify 
additional literatures.  
 
Risk factors for esophageal adenocarcinoma 
Gastro-esophageal reflux causing the premalignant condition Barrett’s esophagus and 
obesity are two major established risk factors for EAC. The risk of EAC in individuals with 
reflux symptoms at least weekly is as high as 5 times that in those without reflux.
8
 Obesity is 
associated with an increased risk of EAC in a seemingly linear pattern.
9-11
  Moreover, tobacco 
smoking and low intake of fruit and vegetables also increase the risk of EAC,
12, 13
 while H. pylori 
infection is associated with a decreased risk of this disease.
14, 15
 All these established 
environmental risk factors seem to explain the majority of EAC cases. It has been estimated that 
combinations of reflux, overweight, tobacco smoking, and low intake of fruit and vegetables 
could account for nearly 80% of EAC cases. 
16, 17
  Studies also indicate a reduced risk of EAC 
associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) or statins, but large 
randomized controlled trials with sufficient follow-up are needed.
1, 18, 19
 A recent pooled analysis 
of population-based case-control studies revealed a reverse association between height and the 
risk of EAC.
20
  
 
Male predominance 
 A male predominance in the incidence of EAC has been noted worldwide. A global 
assessment indicated an overall male-to-female ratio of 4.4, which ranged from 1.7 in sub-
Saharan Africa to 8.5 in North America.
3
  There are some variations across ethnic groups in the 
male predominance of EAC. In the United States, the highest male-to-female ratio has been 
observed in Hispanics followed by non-Hispanic Whites and then Blacks.
21, 22
 The male 
predominance of EAC is also age-dependent. The sex ratio increases with age until the age of 50-
59 years and decreases thereafter.
21, 23-26
 The incidence ratios of EAC between sexes seem to have 
remained relatively stable during the past four decades.
2, 23
  
 
Explanation of the male predominance by established risk factors 
 The striking male predominance in EAC is not readily explained by established risk 
factors. The prevalence of reflux is virtually the same between the sexes,
27, 28
 and no stronger 
association between reflux and EAC risk has been observed in men.
28
 Rather, a recent pooled 
analysis of five case-control studies revealed slightly higher risk estimates associated with reflux 
in women than in men.
29
 However, reflux disease is seemingly more severe in men than in 
women.
30-32
 Erosive reflux disease has been shown to be a stronger risk factor for EAC than 
nonerosive reflux disease. The magnitude of the association between erosive reflux disease and 
EAC risk is higher in men than in women.
30
 Thus, more severe reflux among men may be a 
factor contributing to the male predominance of EAC. 
 The prevalence of obesity is similar between the sexes.
27
 Existing evidence does not 
support a higher risk of EAC associated with obesity in men compared to women.
9, 28, 33
 It has 
been hypothesized that abdominal adiposity, the typical male fat distribution, may contribute to 
the male predominance of EAC, since abdominal obesity is associated with an elevated risk of 
EAC independent of BMI.
10, 34
 However, a stratified analysis by BMI found no evidence of an 
increased male predominance among overweight individuals compared with lean, which argues 
against abdominal obesity as a factor contributing to the male predominance.
35
 
 Although tobacco smoking is more prevalent in men than in women,
27, 33
 the male 
predominance of EAC is unlikely to be explained by this factor. A cohort study following 2 
million person-years at risk indicated that the male predominance in EAC was similar among 
smokers and non-smokers, and the male-to-female incidence ratio was rather higher among non-
smokers (14.2, 95% confidence interval [CI]: 5.1 - 39.5) than in smokers (7.3, 95% CI: 4.6 - 
11.7).
36
 The association between tobacco smoking and EAC risk was similar between the sexes 
or even slightly stronger in women than in men.
12, 28, 33, 36
   
 The male predominance in EAC seems unlikely to be explained by other etiological 
factors. H. pylori infection and intake of fruit and vegetables are equally distributed between the 
sexes, and their associations with EAC risk are no stronger in men than in women.
27, 28
 The use of 
NSAIDs, which may protect against EAC, is slightly more prevalent in women than in men,
27, 37
 
but there is only a moderate and uncertain association between the use of NSAIDs and EAC risk, 
and the prevalence of long-term users is limited.
1
  
 
Sex hormones and reproductive factors and the male predominance 
 The male predominance in EAC may be due to a delayed development of, on average, 16 
years in women compared with men,
24
 suggesting a protective role of sex hormones and 
reproductive factors in the development of EAC.  
 The hypothesis of sex hormonal influence in the etiology of EAC has been tested in 
patients diagnosed with sex hormone related cancers, namely breast and prostate cancers. If sex 
hormones play a role in the development of EAC, an altered risk of EAC might be evident among 
patients who receive long-term sex hormonal therapy. No significantly increased risk of EAC has 
been observed in breast cancer patients using adjuvant anti-estrogen tamoxifen therapy.
38-41
 
Interestingly however, two register-based studies have found a decreased risk of EAC in patients 
with prostate cancer who might have received anti-androgenic treatment,
42, 43
  although an earlier 
study did not.
44
  
 Epidemiological studies on roles of sex hormonal exposures and reproductive factors on 
EAC risk in general populations are scarce and limited by the low incidence of this disease in 
women (Table 1). Several studies observed moderately reduced risk estimates associated with the 
use of hormone replacement therapy (HRT) in post-menopausal women, but none of them 
individually achieved statistical significance.
45-50
 A recent meta-analysis based on five 
observational studies found a 25% decreased risk of EAC in post-menopausal women compared 
with non-users (relative risk [RR] = 0.75, 95% CI: 0.58-0.98).
51
 None of the previous studies 
supported a reduced risk of EAC associated with use of oral contraceptives.
47-49
 A series of 
epidemiological studies have investigated the associations between EAC risk and reproductive 
factors, including menarche, menopause, childbearing, and breastfeeding, and these have yielded 
conflicting results. A large UK prospective study which followed 1.3 million women for on 
average 9.1 years observed a decreased risk of EAC with increasing age at menarche (RR for per 
year older = 0.89, 95% CI: 0.82-0.95) .
52
 However, no altered risk of EAC has been associated 
with menarche or menopause in other studies.
47, 49
 Most studies revealed no altered EAC risk in 
relation to childbearing history in terms of parity, number of pregnancies, or age at first birth.
46, 47, 
49, 52-55
 However, a decreased risk of EAC associated with breastfeeding has been consistently 
observed.
46, 47, 49, 52, 55
 A pooled analysis of three population-based case-control studies found that 
ever breastfeeding was associated with a 40% reduced risk of EAC and the risk decreased with 
increasing duration of breastfeeding (RR for > 12 months = 0.42, 95% CI: 0.23 - 0.77).
49
 The 
protective role of breastfeeding may be related to increased sex hormonal levels, not only 
estrogens, but also progestogens, and possibly also oxytocin, during pregnancy or breastfeeding. 
A protective effect of the single nucleotide polymorphism (SNP) rs572483 in the progesterone 
receptor (PGR) gene was observed among women carrying the variant G allele, which was not 
observed among men, suggesting that PGR in the sex hormone signaling pathway may be 
associated with the gender differences in EAC risk.
56
 
 Only one study has examined the association between circulating sex hormone levels and 
the risk of EAC. Higher levels of serum testosterone and luteinizing hormone (LH) were 
observed in 25 patients with EAC compared with 8 control subjects, and the testosterone levels in 
EAC patients decreased after curative resection.
57
 Nevertheless, considering the small sample 
size and cross-sectional nature of the study, these findings require confirmation in further 
research.  
 Recent studies also suggest a decreased risk of EAC associated with higher intake of 
dietary phytoestrogens, including lignans, quercetin, resveratrol, and flavonoids.
58-61
 These 
findings indicate a potential useful role of chemoprevention of EAC if the sex hormone 
hypothesis could be further confirmed. 
 Biological mechanisms of sex hormones 
 Sex hormones exert their biological effects through the ligation to nuclear receptors, i.e. 
the estrogen receptors (ERs) alpha (ERα) and beta (ERβ), and the androgen receptors (ARs). ERα 
is predominantly expressed in female sex organs, such as the breast, uterus, and ovaries, and is 
responsible for estrogen-reduced mitogenic signaling in epithelial cells in these organs.
62
 ERβ 
exists not only in sex organs but in a wide range of organs in both sexes,
63
 and has been found to 
be expressed in EAC tissues and adjacent normal esophageal mucosa.
64, 65
  Previous studies have 
shown decreased ERβ expression in various cancer tissues as compared with benign tumors or 
normal tissues.
66
 Possible mechanisms of the inhibition of estrogen on esophageal 
adenocarcinogenesis include induction of cell cycle and growth arrest, and initiating apoptosis in 
cancer cells through ER ligands.
67
 The expression of ARs has also been confirmed in EAC 
tissue.
57, 68
 However, the possible mechanisms for androgen/ARs’ involvement in EAC 
development remain largely unknown. Androgen may induce over-expression of fibroblast 
growth factors (FGFs) or members of their receptors, which have an important role in hormone-
dependent malignancies.
57
 
 
Prognosis and the male predominance 
 The prognosis in patients with EAC is worse than that for most other types of tumors, 
with the overall 5-year survival lower than 15%.
1
 A noteworthy sex difference in prognosis 
among patients with esophageal cancers has been consistently shown. Female patients have 
longer survival than male patents, which might be explained by the differences in extrinsic risk 
factors for mortality, or possibly sex itself. 
69-71
  However, the sex difference in survival was 
apparent only in esophageal squamous cell carcinoma (ESCC) instead of EAC in a large register-
based study in the United States.
69
 The role of sex itself in the prognosis of EAC still needs to be 
verified in further independent studies, considering the lack of information on important possible 
confounders in previous studies.  
 
Esophageal squamous cell carcinoma 
 ESCC is the other main histologic type of esophageal cancer. It accounts for nearly 90% 
of all cases of esophageal cancers worldwide. The global incidence rate of ESCC was 5.2 per 100 
00 (7.2 in men and 2.8 in women) in 2012, and the majority (80%) of ESCC cases occur in 
Central and Southeastern Asia.
3
 Alcohol and tobacco use are major risk factors for ESCC, while 
other factors such as dietary habits, esophageal injury (e.g., hot beverages, caustic injury and 
achalasia) and inherited susceptibilities may also contribute to the risk.
72-76
 
 ESCC is also overrepresented in men, but the male predominance is weaker than that of 
EAC. The global overall male-to-female incidence ratio of ESCC is 2.7, and the highest ratio was 
observed in Eastern Europe (7.8) and the lowest in Northern Africa and Western Asia (1.2).
3
 The 
sex difference in ESCC is likely to be attributable to the two major established environmental 
factors, tobacco smoking and heavy alcohol consumption, given the substantially differential 
prevalence of the exposures between men and women.
77, 78
 Yet, sex hormonal factors might also 
be involved in the development of ESCC. ERβ and ARs are expressed in ESCC tissues.64, 79 In 
vitro studies have shown that the growth of ESCC cells could be inhibited by estrogen and 
enhanced by testosterone,
80
 and overexpression of the AR could induce increases in ESCC cell 
invasion and proliferation.
79
 The epidemiological evidence regarding the effects of sex hormonal 
and reproductive factors on the risk of ESCC is inconclusive.
46-48, 52, 53, 81-84
 Three studies found 
no significant association between HRT and the risk of ESCC,
46, 48, 81
 while a large prospective 
cohort study in the United States observed a 60% decreased risk of ESCC associated with current 
use of HRT in postmenopausal women.
47
 In contrast with EAC, no decreased risk of ESCC has 
been associated with breastfeeding. 
46, 47, 52
  
 
Barrett’s esophagus 
 The metaplasia Barrett’s esophagus precedes EAC, and Barrett’s esophagus is 
characterized by considerable male predominance.  A systematic review and meta-analysis 
comprising 32 studies suggested that the male-to-female ratio for Barrett’s esophagus ranged 
from 1.08 to 4.43 with a pooled overall ratio of 1.95 (95% CI: 1.77- 2.17).
31
  The sex difference 
in Barrett’s esophagus seems not to be explained by differential distributions of the two major 
risk factors, reflux and obesity, between sexes, or stronger associations between these factors and 
the risk of BE in men.
31, 85
 Sex hormones may play a role in the development of Barrett’s 
esophagus. ERβ expression has been detected in Barrett’s esophagus mucosa, but at lower levels 
compared to EAC tissues,
65, 86
 while ARs have not been shown to be implicated in Barrett’s 
oesophagus.
87, 88
  A recent analysis has shown elevated levels of serum free testosterone and 
dihydrotestosterone and lower levels of estrone sulfate in individuals with Barrett’s esophagus 
compared to healthy controls.
89
  
 
Perspectives 
 There is an obvious need for further research to better understand the male predominance 
in EAC. Some areas of research might be of particular interest. First, the notable variation in the 
male predominance of EAC across different populations warrants further investigation. The 
variation could be explained by environmental exposures or intrinsic factors (e.g., genetic 
background). A thorough analysis on the racial and geographical variations with reference to 
possible contributing factors may provide clues for understanding the male predominance in EAC. 
Second, the strong male predominance in EAC is unlikely to be explained by any individual risk 
factor. However, quantitatively evaluating the contributions of combinations of established 
etiological factors is encouraged in future studies, where possible interactions between risk 
factors may provide new knowledge in this respect. Third, investigating the role of sex hormonal 
exposures and reproductive factors needs appropriate sample sizes to ensure sufficient statistical 
power. Most previous epidemiological studies have been under-powered, mainly due to the low 
incidence of EAC in women. Alternatively, the sample sizes can be enlarged when investigating 
the role of extrinsic sex hormonal exposures, for example dietary phytoestrogens and endocrine 
disrupting chemicals, in both sexes. Although meta-analyses combining results from different 
studies could achieve higher statistical power, results from meta-analyses on observational 
epidemiological studies should be interpreted with caution, considering different sources of bias 
and heterogeneities across studies. Instead, pooled analyses of different studies with primary data 
might be a more valid strategy. Fourth, and finally, direct evidence concerning the associations 
between sex hormone levels and EAC risk remains largely unexplored. Case-control studies 
nested in prospective cohorts may be a feasible measure of examining such associations. 
Furthermore, given the possible role of ERβ in the estrogenic protection against EAC, molecular 
epidemiological studies are needed to examine whether inherited predispositions influencing ERβ 
expression are associated with EAC risk or can modify the effect of estrogenic exposures in the 
development of EAC. 
 
Conclusions 
 The reasons for the male predominance of EAC have not been completely understood. It 
seems not to be explained by major established risk factors, although more severe reflux in men 
may be a contributing factor. A protective role of high estrogenic exposures is probably involved 
in the development of EAC. However, epidemiological studies have suffered from insufficient 
statistical power due to the low incidence of EAC in women and the existing evidence remains 
far from conclusive. Yet, synthesized results from meta- and pooled analyses during the past 
decade have generated evidence supporting the sex hormonal hypotheses, particularly the 
strongly protective effect of breastfeeding on the risk of EAC. Valid and large population-based 
studies are encouraged to clarify the role of sex hormonal exposures in the etiology of EAC and 
to identify the specific hormones contributing to the male predominance of EAC. The biological 
mechanisms of the protective role of estrogens in EAC development remain largely unknown, 
although ERβ ligand may play a key role in the protection against EAC development. It is worth 
further investigating whether and how ERβ expression is associated with the development and 
progression of EAC in basic scientific research. Overall, continuing research efforts are in need 
to fully understand the reasons for the male predominance of EAC, which could provide ground-
breaking insights into the etiology of this cancer, and hopefully unravel novel targets for 
prevention and treatment of this aggressive disease with rapid increasing incidence in the 
population. 
 
Table 1. Epidemiological studies examining associations between sex hormonal and reproductive factors and the risk of esophageal adenocarcinoma in general 
populations 
First author and year of 
publication 
Design Setting Number of cases 
/ non-cases 
Main findings 
Hormonal replacement therapy  
Lindblad et al. 2006 
50
 Nested case-control 
study 
UK 1994-2001 299/3191 No association with EAC (RR = 1.17, 95% CI: 0.4-3.32) 
Freedman et al. 2010 
48
 Prospective cohort 
study 
US 1995-2003 25/201 481 No association with EAC (RR = 0.90, 95% CI: 0.54-1.49) 
Cronin-Fenton et al. 2010 
49
 Pooled analysis of 
case-control studies 
Ireland 2002-2004, 
Australia 2001-2005 
99/411 Inverse but not statistically significant association with EAC 
among women aged > 50 years (RR = 0.75, 95% CI: 0.45-1.24) 
Bodelon et al. 2011 
47
 Prospective cohort 
study 
US 1993-2009 23/161 057 Inverse but not statistically significant association with EAC (RR 
for current users = 0.87, 95% CI: 0.35-2.17; RR for past users = 
0.74, 95% CI: 0.20-2.82) 
Yu et al. 2011 
46
 Case-control study China 2008-2010 44/132 No association with EAC risk (RR = 0.88, 95% CI: 0.42-1.79) 
Menon et al. 2014 
45
 Matched cohort 
study 
UK 1987-2008 13/103 689  No association with EAC risk (RR = 0.89, 95% CI: 0.28-2.82) 
Use of oral contraceptives     
Freedman et al. 2010 
48
 Prospective cohort 
study 
US 1995-2003 25/201 481 No association with EAC (RR for 1-10 years= 1.00, 95% CI: 
0.55-1.83; RR for 10 years or longer = 1.50, 95% CI: 0.69-3.28; P 
for trend 0 0.422) 
Cronin-Fenton et al. 2010 
49
 Pooled analysis of 
case-control studies 
Ireland 2002-2004,  
US 1964-1973 
Australia 2001-2005 
138/784 No association with EAC (RR = 0.92, 95% CI: 0.55-1.54) 
Bodelon et al. 2011 
47
 Prospective cohort 
study 
US 1993-2009 23/161 057 No association with EAC (RR = 0.92, 95% CI: 0.37-2.28) 
Menarche and menopause     
Cronin-Fenton et al. 2010 
49
 Pooled analysis of 
case-control studies 
Ireland 2002-2004,  
US 1964-1973 
Australia 2001-2005 
142/786 No association between age at menarche and EAC (RR for over 
13 years = 1.01 (95% CI: 0.35-2.91) compared with 13 years or 
younger); 
No significant association  between age at menopause and EAC 
[RRs (95% CIs) for below 50 years and pre-menopause = 1.06 
(0.64-1.77) and 0.65 (0.17-2.50), respectively, compared with 50-
70 years] 
Bodelon et al. 2011 
47
 Prospective cohort 
study 
US 1993-2009 23/161 057 No association between age at menarche and EAC [RRs (95% 
CIs) for 12, 13, 14, and 15 years or above = 1.07 (0.30-3.79), 0.59 
(0.15-2.36), 0.70 (0.15-3.15), and 0.72 (0.18-2.91), respectively];  
No association  between age at menopause and EAC [RRs (95% 
CIs) for 45-49, 50-54, and 55 years or above = 2.55 (0.70-9.30), 
1.33 (0.31-5.78), and 2.63 (0.54-12.77), respectively, with less 
than 45 years as reference]  
Yu et al. 2011 
46
 Case-Control study China 2008-2010 44/132 No association between age of menarche and EAC (RR for over 
13 years = 1.02, 95% CI: 0.51-2.23, compared with 13 years or 
younger); 
Increased risk of EAC associated with menopause at ages < 45 
years (RR = 2.57, 95% CI: 1028-7.10) compared with at ages >50 
years 
Green et al. 2012 
52
 Prospective cohort 
study 
UK 1996-2008 399/1 319 010 No association between age at menarche and EAC [RRs (95% 
CIs) for < 13 and ≥ 15 years = 1.29 (1.04-1.60) and 0.80 (0.59-
1.10), respectively, compared with 13-14 years]; a decrease in 
EAC risk with increasing age at menarche treated as a continuous 
variable (RR per year older = 0.89, 95% CI: 0.82-0.95). 
No association between age at menopause and EAC [RRs (95% 
CIs) for 45-49 and < 45 years or above = 1.12 (0.80-1.57) and 
0.89 (0.54-1.47), respectively, compared with 50 years or above]. 
Childbearing     
Cheng et al. 2000 
55
 Case-control study UK 1993-1996 74/74 No association between number of children and EAC [RRs (95% 
CIs) for 1-2 and 3 or more = 0.46 (0.16-1.31) and 0.69 (0.23-
2.01), respectively, compared with no children] 
Lagergren et al. 2005 
54
 Case-control study Sweden 1995-1997 63/141 No association between parity and EAC (RR for non-parous = 
0.82, 95% CI: 0.25-2.73, compared with parous women); 
No association between number of children, age at first birth, or 
years between first and last birth, and EAC 
Yu et al. 2011 
46
 Case-Control study China 2008-2010 44/132 No significant association between being ever pregnant and EAC 
risk (RR = 0.79, 95% CI: 0.09-45.8); 
No association between age at first birth and EAC [RRs (95% 
CIs) for 23-26 and > 26 years = 1.12 (0.41-4.12) and 2.95 (0.97-
11.1), respectively, compared with younger than 23 years] 
Lu et al. 2012 
53
 Nested case-control 
study 
Sweden 1932-2008 115/1150 No association between parity and EAC (RR for parous = 0.66, 
95% CI: 0.38-1.14, compared with non-parous women); 
No significant association between number of children or age at 
first birth and EAC risk 
Cronin-Fenton et al. 2010 
49
 Pooled analysis of 
case-control studies 
Ireland 2002-2004,  
US 1964-1973, 
UK 1993-1996, 
Australia 2001-2005 
218/862 Being ever pregnant not associated with an altered risk of 
adenocarcinoma of esophagus and gastric cardia (RR = 1.02, 95% 
CI: 0.55-1.87); 
No association between number of children and EAC 
Bodelon et al. 2011 
47
 Prospective cohort 
study 
US 1993-2009 23/161 057 No association between number of term pregnancies or age at 
first term pregnancy and EAC 
Green et al. 2012 
52
 Prospective cohort 
study 
UK 1996-2008 399/1 319 010 No significant association between number of term pregnancies 
or age at first birth and EAC 
Breastfeeding     
Cheng et al. 2000 
55
 Case-control study UK 1993-1996 74/74 Breastfeeding was associated with a reduced risk of EAC (RR = 
0.41, 95% CI: 0.20-0.82; RR for over 6 months = 0.31, 95% CI: 
0.09-1.02) 
Cronin-Fenton et al. 2010 
49
 Pooled analysis of 
case-control studies 
Ireland 2002-2004,  
UK 1993-1996, 
Australia 2001-2005 
165/565 Breastfeeding was associated with a reduced risk of EAC (RR = 
0.58, 95% CI: 0.37-0.92; RR for over 12 months = 0.42, 95% CI: 
0.23-0.77) 
Bodelon et al. 2011 
47
 Prospective cohort 
study 
US 1993-2009 23/161 057 Inverse but not statistically significant association between 
breastfeeding and EAC (RR = 0.44, 95% CI: 0.18-1.07) 
Yu et al. 2011 
46
 Case-Control study China 2008-2010 44/132 Breastfeeding for over 12 months associated with a reduced risk 
of EAC (RR = 0.40, 95% CI: 0.13-0.92) 
Green et al. 2012 
52
 Prospective cohort 
study 
UK 1996-2008 399/1 319 010 Breastfeeding associated with a reduced risk of EAC (RR = 0.75, 
95% CI: 0.58-0.97) 
CI: confidence interval; EAC: esophageal adenocarcinoma; RR: relative risk; 
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